Trending...
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities
HORSHAM, Pa., April 9, 2024 ~ Myonex, a leading global clinical trial supply company, has recently announced the completion of its acquisition of SaveWay Compounding Pharmacy in Newark, Delaware. The pharmacy will now operate as SaveWay Compounding Pharmacy, a Myonex company.
This strategic move by Myonex is part of their ongoing efforts to support clinical trial sponsors' trial designs with direct-to-patient (DTP) and home healthcare provider (HHP) capabilities. With this acquisition, Myonex aims to provide wider patient access across the entire United States and support patients in obtaining the necessary trial medication and equipment.
According to James Lovett, Chief Executive Officer at Myonex, "SaveWay's pharmacy capabilities complement and extend our existing clinical supplies solutions within the US. SaveWay will provide additional access for drug sourcing and direct-to-patient options across all 50 states for our clinical packaging and labeling and ancillary supply services." This will also complement Myonex's market-leading CTRx™ to offer a full suite of prescription-based supply options for both investigational medicinal product (IMP) and commercial drug access throughout the US. These added capabilities will enable Myonex to better serve their clients' needs and facilitate decentralized clinical trials (DCT) and hybrid studies.
More on The PennZone
The acquisition also presents an opportunity for SaveWay to expand into the realm of clinical trials and accelerate the growth of their direct-to-patient services. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed excitement about this partnership: "We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today's trends in clinical trials."
This recent acquisition announcement comes on the heels of another significant acquisition by Myonex – that of Creapharm – further solidifying their commitment to providing faster, more flexible, and reliable services to their clients while improving the clinical trial patient experience. With these acquisitions, Myonex now boasts one of the most diverse clinical trial supply service offerings globally.
Myonex was exclusively advised by Crosstree as its financial advisor and Troutman Pepper as its legal advisor in this acquisition of SaveWay. This partnership is expected to bring about significant growth and success for both companies in the clinical trial supply industry.
This strategic move by Myonex is part of their ongoing efforts to support clinical trial sponsors' trial designs with direct-to-patient (DTP) and home healthcare provider (HHP) capabilities. With this acquisition, Myonex aims to provide wider patient access across the entire United States and support patients in obtaining the necessary trial medication and equipment.
According to James Lovett, Chief Executive Officer at Myonex, "SaveWay's pharmacy capabilities complement and extend our existing clinical supplies solutions within the US. SaveWay will provide additional access for drug sourcing and direct-to-patient options across all 50 states for our clinical packaging and labeling and ancillary supply services." This will also complement Myonex's market-leading CTRx™ to offer a full suite of prescription-based supply options for both investigational medicinal product (IMP) and commercial drug access throughout the US. These added capabilities will enable Myonex to better serve their clients' needs and facilitate decentralized clinical trials (DCT) and hybrid studies.
More on The PennZone
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
- Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
The acquisition also presents an opportunity for SaveWay to expand into the realm of clinical trials and accelerate the growth of their direct-to-patient services. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed excitement about this partnership: "We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today's trends in clinical trials."
This recent acquisition announcement comes on the heels of another significant acquisition by Myonex – that of Creapharm – further solidifying their commitment to providing faster, more flexible, and reliable services to their clients while improving the clinical trial patient experience. With these acquisitions, Myonex now boasts one of the most diverse clinical trial supply service offerings globally.
Myonex was exclusively advised by Crosstree as its financial advisor and Troutman Pepper as its legal advisor in this acquisition of SaveWay. This partnership is expected to bring about significant growth and success for both companies in the clinical trial supply industry.
Filed Under: Business
0 Comments
Latest on The PennZone
- The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
- Corner Property Management AAMC Awarded Community Management Contract for Belvidere at Doyle Square
- Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
- TrueDriveCost Launches Free Calculators for the Real Cost of Owning a Car
- A New Era Of Social Networking Is Here !
- Poetry Quarterly Returns in Print With Its Fall 2026 Issue, Featuring 42 Poets
- HIRO Ostomy Belt Launch by Richard O'Hamill
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- The Well Woman Conference Comes To Philadelphia: A Powerful Experience Of Faith And Healing
- No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
- The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
- Pittsburgh Family Law Firm Pollock Begg Celebrates 16th Consecutive Best Law Firms Ranking
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
- A Powerful Encounter Awaits Philadelphia: Dr. Mattie Nottage Joins Brother Marcus on Air
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- Beyond Spots & Dots Spreads Holiday Cheer at Old Economy Village's Festival of Trees
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!